Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
European Urology Focus|September 18, 2021
Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort StudyAnke Richters, Joost L Boormans, Michiel S van der Heijden, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 28, 2015
Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancerShafak Aluwini, Wendy M H Busser, Wendimagegn Ghidey Alemayehu, et al.
BJU International|September 3, 2025
Carbon footprint and staff demands of surgery and chemoradiation for muscle-invasive bladder cancerVera C Rutten, Simone A W Hesseling, Martine Franckena, et al.
European Urology Oncology|September 26, 2024
Risk of progression in patients with primary T1 high grade non-muscle invasive bladder cancer - a contemporary cohortOlga M Pijpers, Lisa M C van Hoogstraten, Sebastiaan Remmers, et al.
BJU International|December 4, 2024
The impact of positive surgical margins after cystectomy on oncological outcomes: a nationwide studyJikke Bosveld, Tri Q Nguyen, Joost L Boormans, et al.
The Journal of Urology|February 20, 2020
A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up StagingJoep J de Jong, Yang Liu, Stephen A Boorjian, et al.
Cell Genomics|March 29, 2024
Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signatureJ Alberto Nakauma-González, Maud Rijnders, Minouk T W Noordsij, et al.
European Urology|September 1, 2009
Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancerJoost L Boormans, Karin G Hermans, Angelique C J Ziel-van der Made, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 9, 2016
Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder CancerKim E M van Kessel, Lorraine M de Haan, Elisabeth E Fransen van de Putte, et al.
European Urology Open Science|March 18, 2024
A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with RadiotherapyFlorus C de Jong, Iris G Iflé, Angelique C van der Made, et al.
Pageof 11